**Table S1.** Primers used in this study

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Target or purpose** | **PCR**  **product** | **Primer name** | **Sequence (5’-3’)** | **Product size (bp)** | **Reference** |
| Tn*1721* on pKP048 | J1 | Tn1721-1F | 5'-ACCTTTGATGGTGGCGTAAG-3' | 352 | S1 |
| Tn1721-1R | 5'-GGGAGCACATCAACCTAACC-3' |
| M1 | Tn1721-2F | 5'-GTCGGAGTCGTTGAAGGTGT-3' | 447 | S1 |
| Tn1721-2R | 5'-CGCTTGGTACAGAAGCTGACT-3' |
| M2 | Tn1721 -3F | 5'-ACCACCACTGTATCGCCTTC-3' | 2243 | S1 |
| Tn1721 -3R | 5'-GCCCTTTCATTTGCTGGTAA-3' |
| M3 | Tn1721-4F | 5'-ATTGCTTATGGTGCCTGGTC-3' | 1474 | S1 |
| Tn1721-4R | 5'-TATGGCACGGCAAATGACTA-3' |
| M4 | Tn1721-5F | 5'-CGAGTTTAGCGAATGGTTCC-3' | 592 | S1 |
| Tn1721-5R | 5'-TATCAGCGACATCGTCAACC-3' |
| M5 | Tn1721-6F | 5'-CATGCGACTTGTCTTCAGGA-3' | 413 | S1 |
| Tn1721-6R | 5'-GTACCGTGGACAGGAACGTC-3' |
| M6 | Tn1721-7F | 5'-TCCTCCACCTTCATCCTCAG-3' | 3217 | This study |
| Tn1721-7R2 | 5'-GAGAGGCGTGCGATATCTTC-3' |
| J2 | Tn1721-7F | 5'-TCCTCCACCTTCATCCTCAG-3' | 413 | S1 |
| Tn1721-7R | 5'-ATATCACGAATCCCGAGCTG-3' |
| J3 | Tn1721-8F | 5'-GGTGAAACACTGAATGATGAA-3' | 1802 | S1 |
| Tn1721-8R | 5'-GTTTGATGATGTGACTGGAGA-3' |
| Tn*1721*-IS*26* on pKPHS2 | J4 | Tn1721-9F | 5'-GGATGCCTTGTCGGTAAAGA-3' | 410 | This study |
| Tn1721-9R | 5'-CAACGTGAAGAAGTGGCAGA-3' |
| J5 | Tn1721-10F | 5'-GTAACTGATGCCGTATTTGC-3' | 1536 | This study |
| Tn1721-10R | 5'-ATTTTCAGAAGACGACTGCAC-3' |

**Reference**

S1**.** Li G, Zhang Y, Bi D, et al. First report of a clinical, multi-drug resistant *Enterobacteriaceae* isolate co-harboring fosfomycin resistance gene *fosA3* and cabarpenemase gene *bla*KPC-2 on the same transposon, Tn*1721*. Antimicrob Agents Chemother. 2014; 59: 338-43.